PsoProtect, the global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data so that it now includes the first 200 cases.
The registry has received cases from all over the world.
The aim of PsoProtect is to better our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis.
In addition to demographics, PsoProtect collects the following types of de-identified data:
- Psoriasis disease characteristics, comorbidities and systemic treatment for psoriasis at onset of COVID-19
- COVID-19 characteristics and disease course
- COVID-19 outcome
View the full report of PsoProtect's current data here.
We encourage clinicians to continue reporting cases of COVID-19 (suspected or confirmed) in psoriasis via the simple online PsoProtect case report form.
*Data are preliminary and include a limited number of cases and should not be used to inform clinical decision making.